本文已被：浏览 1442次 下载 1415次
投稿时间：2022-10-31 网络发布日期：2023-06-20
投稿时间：2022-10-31 网络发布日期：2023-06-20
中文摘要: 肺肉瘤样癌是一种罕见的非小细胞肺癌,症状隐匿,侵袭性强,传统治疗手段疗效欠佳,预后较差。近年来,基于分子分型、液体活检技术的发展,对肺肉瘤样癌的分子生物学特点有了较为深刻的认识,新型的分子靶向和免疫治疗药物的问世,使其临床疗效得到了明显的提高。本文回顾了肺肉瘤样癌的研究进展,特别是有关分子靶向治疗和免疫治疗的新进展,以期为临床治疗提供参考。
Abstract:Pulmonary sarcomatoid carcinoma (PSC) is a kind of rare non-small cell lung cancer (NSCLC) with insidious symptoms, strong invasiveness, insensitiveness to traditional treatments and poor prognosis. With the development of molecular typing and liquid biopsy techniques in recent years, the molecular biological characteristics of PSC have been understanded deeply. Furthermore, the clinical efficacy has been significantly improved owing to novel molecular targeting therapeutic and immunotherapeutic agents. Based on the recent advances in the management of PSC, this article especially focuses on the progress on molecular targeted therapy and immunotherapy in order to provide some reference for clinical practice.
keywords: Pulmonary sarcomatoid carcinoma Molecular targeted therapy Immunotherapy Immune checkpoint inhibitor Tumor mutation burden Tyrosine kinase inhibitor Non-small cell lung cancer
文章编号： 中图分类号：R734.2 文献标志码：A
基金项目:陕西省自然科学基础研究计划资助项目 (2021JM-582)
引用文本：
高芝兰,郑琪,白杰,等.肺肉瘤样癌精准治疗研究进展[J].中国临床研究,2023,36(6):810-815,820.
高芝兰,郑琪,白杰,等.肺肉瘤样癌精准治疗研究进展[J].中国临床研究,2023,36(6):810-815,820.